This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

CERTAIN: CIMZIA in Rheumatoid Arthritis, final version 29-Oct-2007

  • Research type

    Research Study

  • Full title

    A Phase IIIB Multicenter, double-blind randomised, placebo-controlled parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti- TNFá Fab' fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis

  • Contact name

    Paul Emery

  • Contact email

  • Sponsor organisation

    UCB Pharma S.A.

  • Eudract number


  • ISRCTN Number


  • Research summary

    Research Summary not published at request of reseacher

  • REC name

    Yorkshire & The Humber - Leeds East Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    5 Feb 2009

  • REC opinion

    Further Information Favourable Opinion